Moderna, Inc. (MRNA)

Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $80.65B
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Latest financial period: September 30, 2026
Filed with the SEC: November 6, 2026
Estimated earnings date: Not available
Profit #1327 of 1422 companies
| | Sep 26 | Jun 26 | Mar 26 | Dec 25 |
|---|
| ROE/ROA | 5.0% | 5.2% | 5.1% | 5.8% |
Growth #579 of 1422 companies
Payout #1089 of 1422 companies
Safety #936 of 1422 companies
Price #1343 of 1422 companies